Forecast

The analysts' average price target is +129,77€ (+2,07%). The median is +130,84€ (+2,91%).

Buy	38
Hold	19
Sell	1

News Go to news feed

Gilead receives EU approval for Trodelvy in combination with Keytruda for triple-negative breast cancer

The European Commission has approved Trodelvy (sacituzumab govitecan) in combination with Keytruda (pembrolizumab) for adult women with inoperable or metastatic, PD‑L1‑positive (CPS≥10) triple‑negative breast cancer. The decision applies to the 27 EU member states as well as Norway, Iceland and Liechtenstein and is based on data from the phase‑III ASCENT‑04/KEYNOTE‑D19 study. The combination reduced the risk of disease progression or death by 35% versus standard chemotherapy plus Keytruda. » More on de.investing.com
Gilead outpaces Pfizer with clearer growth trajectory

Gilead reported stronger underlying expansion, with product sales excluding Veklury up 10% and HIV revenue rising 12%, driven by Biktarvy, Descovy and the growing Yeztugo launch, while oncology and liver-disease drugs also contributed. Pfizer showed gains from its non-COVID portfolio—launched and acquired products grew 18%—and raised revenue guidance, but overall operational growth was only 1% and the company faces patent headwinds. Gilead's growth is broader today, whereas Pfizer remains an execution-dependent turnaround supported by cost savings and newer product ramps. » More on finance.yahoo.com
Gilead's HIV franchise fuels Q2 revenue growth but increases concentration risk

Gilead reported Q2 2026 revenue up about 10% to ~$7.8 billion, led by HIV product sales of roughly $5.7 billion, or about three-quarters of product sales. New HIV launch Yeztugo posted $232 million and Biktarvy and Descovy also grew, while the liver-disease portfolio rose 10% to $877 million. Management raised full-year product-sales guidance, but the company booked an $11.2 billion non-cash loss tied to recent acquisitions as it pays to diversify beyond HIV. Heavy reliance on the HIV franchise and uneven performance in oncology present longer-term commercial and competitive risks. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Gilead Sciences has already paid 1,44€ in dividends. The last payout was in June.

Financials

In the last quarter, Gilead Sciences had revenue of 6.84b€ and net profit of −9.20b€

(EUR)	Jun 2026	YoY
Revenue	+6.84b	13,81%
Gross profit	+5.45b	15,19%
Net profit	−9.20b	653,05%
EBITDA	−8.77b	406,31%

Fundamentals

Metric	Value
Market capitalization	+158.37b€
Number of shares	1.24b
52-week high/low	+134,95€ - +93,06€
Dividend yield	+2,18%
Dividends TTM	+2,78€
Beta	0,34
P/E ratio	−57,18
PEG ratio	+0,38
P/B ratio	+15,62
P/S ratio	+6,06

Company profile

Das biopharmazeutische Unternehmen Gilead Sciences, Inc. erforscht, entwickelt und vermarktet Medikamente in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international. Das Unternehmen bietet die Produkte Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild und Atripla für die Behandlung von HIV/AIDS; Veklury, eine Injektion zur intravenösen Anwendung, für die Behandlung der Coronavirus-Krankheit 2019; und Epclusa, Harvoni, Vosevi, Vemlidy und Viread für die Behandlung von Lebererkrankungen. Es bietet auch Yescarta, Tecartus, Trodelvy und Zydelig Produkte für die Behandlung von Hämatologie, Onkologie und Zelltherapie Patienten. Darüber hinaus bietet das Unternehmen Letairis, eine orale Formulierung zur Behandlung der pulmonalen arteriellen Hypertonie, Ranexa, eine orale Formulierung zur Behandlung der chronischen Angina pectoris, und AmBisome, eine liposomale Formulierung zur Behandlung schwerer invasiver Pilzinfektionen. Gilead Sciences, Inc. hat Kooperationsvereinbarungen mit Arcus Biosciences, Inc; Pionyr Immunotherapeutics Inc; Tizona Therapeutics, Inc; Tango Therapeutics, Inc; Jounce Therapeutics, Inc; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc; und Merck & Co, Inc. Das Unternehmen wurde 1987 gegründet und hat seinen Hauptsitz in Foster City, Kalifornien.